nach oben

Clinical Rheumatology

Erschienen in:

01.05.2020 | Original Article

Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab

verfasst von: Marta Casal Moura, Alvise Berti, Karina A. Keogh, Gerald W. Volcheck, Ulrich Specks, Misbah Baqir

Erschienen in: Clinical Rheumatology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Rituximab (RTX) treatment is used for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, but its benefits in eosinophilic granulomatosis with polyangiitis (EGPA) are unclear. Our aim was to characterize asthma control and glucocorticoid (GC) sparing after RTX treatment.

Methods

A retrospective, computer-assisted search was performed to identify patients with EGPA and GC-dependent asthma diagnosed between 2000 and 2017 who received RTX for remission induction. Demographic and clinical features were analyzed.

Results

Of the 17 patients included, the majority were myeloperoxidase-ANCA positive (n = 13, 76.5%). Uncontrolled asthma symptoms and atopy were present in 13 patients (76.5%). RTX was used for initial remission induction in patients with new onset of severe disease (n = 5, 29.4%) and after failed remission induction with other immunosuppression (n = 12, 70.6%). It was used for remission maintenance in nine patients (52.9%). GCs were used for maintenance at a median dose of 25 mg/day (interquartile range, 16.25–37.5). At the end of follow-up, 13 patients (76.5%) had non-severe or controlled asthma, and remission was achieved in 12 (70.6%). Median serum eosinophil and C-reactive protein values decreased (1.06 vs 0.10 × 10⁹/L [P = .012] and 27.0 vs 5.0 mg/dL [P = .001], respectively), whereas pulmonary function test results remained unchanged. Median GC dose was significantly reduced at 6, 12, 18, and 24 months (P < .0001). Patients receiving RTX for maintenance required less than 10 mg of GCs for asthma control.

Conclusion

RTX seems to be safe and have GC-sparing efficacy for asthma control in EGPA. Randomized controlled trials are needed for detailed study of RTX for treating EGPA.

Key Points

• In this retrospective study we have concluded that rituximab (RTX) might be considered for the control of severe corticosteroid-dependent asthma in eosinophilic granulomatosis polyangiitis (EGPA) patients especially when myeloperoxidase antibodies are positive.

• Rituximab has not been studied particularly for asthma control in EGPA patients.

• The most noticeable effect of RTX was the decrease in the use of corticosteroids for the control of asthma.

Churg J, Strauss L (1951) Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 27(2):277–301PubMedPubMedCentral

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, Group R-IR (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232. https://doi.org/10.1056/NEJMoa0909905 PubMedPubMedCentralCrossRef

Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH, Group R-IR (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369(5):417–427. https://doi.org/10.1056/NEJMoa1213277 PubMedPubMedCentralCrossRef

Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quemeneur T, Blanchard-Delaunay C, Godmer P, Puechal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L, French Vasculitis Study G (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371(19):1771–1780. https://doi.org/10.1056/NEJMoa1404231 PubMedCrossRef

Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, Dalhoff K, Dunogue B, Gross W, Holle J, Humbert M, Jayne D, Jennette JC, Lazor R, Mahr A, Merkel PA, Mouthon L, Sinico RA, Specks U, Vaglio A, Wechsler ME, Cordier JF, Guillevin L (2015) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) consensus task force recommendations for evaluation and management. Eur J Intern Med 26(7):545–553. https://doi.org/10.1016/j.ejim.2015.04.022 PubMedCrossRef

Keogh KA, Specks U (2006) Churg-Strauss syndrome. Semin Respir Crit Care Med 27(2):148–157. https://doi.org/10.1055/s-2006-939518 PubMedCrossRef

Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, Savage CO, Jayne DR (2009) A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60(7):2156–2168. https://doi.org/10.1002/art.24637 PubMedCrossRef

Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D, Pusey CD, Salama AD (2008) Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 47(7):1104–1105. https://doi.org/10.1093/rheumatology/ken175 CrossRef

Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC (2011) Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 26(9):2865–2871. https://doi.org/10.1093/ndt/gfq852 PubMedPubMedCentralCrossRef

10.

Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry MJ, Amudala N, Smith R, Sivasothy P, Guillevin L, Merkel PA, Jayne DR (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 75(2):396–401. https://doi.org/10.1136/annrheumdis-2014-206095 PubMedCrossRef

11.

Hellmich B, Csernok E, Gross WL (2005) Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci 1051:121–131. https://doi.org/10.1196/annals.1361.053 PubMedCrossRef

12.

Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey SW, Steinfeld J, Weller PF, Gleich GJ, Team EMS (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376(20):1921–1932. https://doi.org/10.1056/NEJMoa1702079 PubMedPubMedCentralCrossRef

13.

Thiel J, Hassler F, Salzer U, Voll RE, Venhoff N (2013) Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther 15(5):R133. https://doi.org/10.1186/ar4313 PubMedPubMedCentralCrossRef

14.

Berti A, Cornec D, Moura MC, Smith R, Dagna L, Specks U, Keogh K (2019) 129. Respiratory involvement in patients with eosinophilic granulomatosis with polyangiitis: clinical and serological predictors of long-term asthma severity. Rheumatology 58(Supplement_2). https://doi.org/10.1093/rheumatology/kez059.006

15.

Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33(8):1094–1100. https://doi.org/10.1002/art.1780330806 PubMedCrossRef

16.

Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43(2):343–373. https://doi.org/10.1183/09031936.00202013 PubMedCrossRef

17.

Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68(12):1827–1832. https://doi.org/10.1136/ard.2008.101279 PubMedCrossRef

18.

Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40(2):371–380. https://doi.org/10.1002/art.1780400222 PubMedCrossRef

19.

Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, Thibult N, Casassus P (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75(1):17–28. https://doi.org/10.1097/00005792-199601000-00003 CrossRef

20.

Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, Sinico RA, Sivasothy P, Wechsler ME, Groh M, Marchand-Adam S, Khouatra C, Wallaert B, Taille C, Delaval P, Cadranel J, Bonniaud P, Prevot G, Hirschi S, Gondouin A, Dunogue B, Chatte G, Briault A, Jayne D, Guillevin L, Cordier JF, the Groupe d'Etudes et de Recherche sur les Maladies Orphelines P (2016) Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J 48(5):1429–1441. https://doi.org/10.1183/13993003.00097-2016 PubMedCrossRef

21.

Thiel J, Troilo A, Salzer U, Schleyer T, Halmschlag K, Rizzi M, Frede N, Venhoff A, Voll RE, Venhoff N (2017) Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract 5(6):1556–1563. https://doi.org/10.1016/j.jaip.2017.07.027 PubMedCrossRef

22.

Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR (2012) Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64(11):3760–3769. https://doi.org/10.1002/art.34583 PubMedCrossRef

23.

Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Lauque D, Puechal X, Letellier P, Delaval P, Cordier JF, Guillevin L, French Vasculitis Study G (2008) Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58(2):586–594. https://doi.org/10.1002/art.23198 PubMedCrossRef

24.

Teixeira V, Mohammad AJ, Jones RB, Smith R, Jayne D (2019) Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open 5(1):e000905. https://doi.org/10.1136/rmdopen-2019-000905 PubMedPubMedCentralCrossRef

25.

Cottin V, Khouatra C, Dubost R, Glerant JC, Cordier JF (2009) Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Allergy 64(4):589–595. https://doi.org/10.1111/j.1398-9995.2008.01854.x PubMedCrossRef

26.

Berti A, Volcheck GW, Cornec D, Smyth RJ, Specks U, Keogh KA (2018) Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respir Med 142:66–72. https://doi.org/10.1016/j.rmed.2018.07.017 PubMedCrossRef

27.

Emmi G, Rossi GM, Urban ML, Silvestri E, Prisco D, Goldoni M, Vaglio A (2018) Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 77(6):952–954. https://doi.org/10.1136/annrheumdis-2017-211897 PubMedCrossRef

28.

Thiel J, Rizzi M, Engesser M, Dufner AK, Troilo A, Lorenzetti R, Voll RE, Venhoff N (2017) B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther 19(1):101. https://doi.org/10.1186/s13075-017-1306-0 PubMedPubMedCentralCrossRef

29.

Baqir M, Garrity JA, Vassallo R, Witzig TE, Ryu JH (2016) Asthma and orbital immunoglobulin G4-related disease. Ann Allergy Asthma Immunol 116(4):313–316. https://doi.org/10.1016/j.anai.2015.12.003 PubMedCrossRef

30.

Puechal X, Pagnoux C, Baron G, Quemeneur T, Neel A, Agard C, Lifermann F, Liozon E, Ruivard M, Godmer P, Limal N, Mekinian A, Papo T, Ruppert AM, Bourgarit A, Bienvenu B, Geffray L, Saraux JL, Diot E, Crestani B, Delbrel X, Sailler L, Cohen P, Le Guern V, Terrier B, Groh M, Le Jeunne C, Mouthon L, Ravaud P, Guillevin L, French Vasculitis Study G (2017) Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic Polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheum 69(11):2175–2186. https://doi.org/10.1002/art.40205 CrossRef

31.

Puechal X, Pagnoux C, Baron G, Lifermann F, Geffray L, Quemeneur T, Saraux JL, Wislez M, Cottin V, Ruivard M, Limal N, Aouba A, Bonnotte B, Neel A, Agard C, Cohen P, Terrier B, Le Jeunne C, Mouthon L, Ravaud P, Guillevin L, French Vasculitis Study Group i (2019) Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. Rheumatology (Oxford) doi:https://doi.org/10.1093/rheumatology/kez139

32.

Vaglio A, Moosig F, Zwerina J (2012) Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol 24(1):24–30. https://doi.org/10.1097/BOR.0b013e32834d85ce PubMedCrossRef

33.

Cornec D, Cornec-Le Gall E, Specks U (2017) Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn. Nephrol Dial Transplant 32(suppl_1):i37–i47. https://doi.org/10.1093/ndt/gfw384 PubMedCrossRef

Titel: Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab
verfasst von: Marta Casal Moura
Alvise Berti
Karina A. Keogh
Gerald W. Volcheck
Ulrich Specks
Misbah Baqir
Publikationsdatum: 01.05.2020
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 5/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-019-04891-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Presence of active MRI lesions in patients suspected of non-radiographic axial spondyloarthritis with high disease activity and chance at conversion after a 6-month follow-up period

Evaluation of cognitive function in systemic sclerosis patients: a pilot study

Is the prevention of rheumatoid arthritis possible?

Antiphospholipid antibodies in patients with proliferative and membranous lupus nephritis

Ultra-processed food consumption associates with higher cardiovascular risk in rheumatoid arthritis